EDG-15400
Targeting Heart Failure
We are developing EDG-15400, a selective cardiac sarcomere modulator, for the treatment of heart failure and other diseases of cardiac diastolic dysfunction.
About HFpEF
HFpEF is a common form of heart failure cases in the US and is on the rise. Key risk factors include advanced age, high blood pressure, kidney dysfunction, and obesity. Hospitalization rates for HFpEF are high, with approximately 20-30% of patients readmitted within 30 days, and it is associated with significant morbidity and mortality, with 5-year mortality rates around 50-60%.
HFpEF profoundly affects patients, causing symptoms such as shortness of breath, limb swelling, fatigue, weakness, wheezing, nausea, and loss of appetite. These symptoms, which vary from mild to severe and may fluctuate, disrupt daily routines and often intensify over time, significantly diminishing quality of life. For many, the quality of life is lower than that experienced with many other chronic conditions.
At the core of HFpEF lies diastolic dysfunction, which impairs the heart’s ability to relax and fill with blood. Current HFpEF treatments may not be right for everyone. New medicines are needed to better address the challenges of HFpEF.
About EDG-15400
Targeting the sarcomere
EDG-15400 is a novel oral, selective cardiac sarcomere modulator for the treatment of heart failure.
Potential to address HFpEF
EDG-15400 may help address the health challenges of HFpEF, which is characterized by cardiac diastolic dysfunction.
In the clinic
EDG-15400 is currently being studied in a Phase 1 trial of healthy adults.
EDG-15400 is an investigational therapy that has not been approved for use in heart failure or any cardiac disease by any regulatory agency, as its safety and effectiveness have not been established for the treatment of these diseases.
